###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
###end article-title 0
###begin p 1
###xml 403 411 <span type="species:ncbi:9606">patients</span>
Wrote the paper: RC PEL. Designed the study concept, wrote the clinical protocol and supervised the study integrating the different parts, were responsible for central data monitoring, supervised selection of molecular parameters: PEL. Performed most of the laboratory experiments and did the statistical analysis: RC. Did the functional assays and revised the manuscript: SK. Recruited and treated the patients participating in the study: EL GA BO SL TR IM. Participated in central data monitoring: EL BO. Participated in protocol discussions, approval and amendements: EL GA BO SL TR IM. Established the Chk2 kinase assay: EOB. Responsible for genetical counseling and collection of data for the CHEK2 germline mutated families: LM LFE. Supervised all the laboratory analysis and participated in and supervised: JRL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 288 295 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 459 463 459 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 553 557 553 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 635 636 635 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 812 820 812 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 900 905 900 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 913 918 913 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 910 918 910 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 951 956 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 963 968 963 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 960 968 960 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis or global gene expression profiles have failed to identify mechanisms causing in vivo resistance to anthracyclines. While we previously found TP53 mutations in the L2/L3 domains to be associated with drug resistance, some tumors harboring wild-type TP53 were also therapy resistant. The aim of this study was; 1) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m2 every 3 week) in patients with primary, locally advanced breast cancer; 2) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer; 3) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14(ARF) genes; and 4) Explore potential CHEK2 or p14(ARF) germline mutations with respect to family cancer incidence.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 116 127 116 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CHEK2</italic>
###xml 135 140 135 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 132 140 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 190 195 190 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP5</italic>
###xml 316 317 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 397 402 397 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 462 463 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 565 566 565 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 625 626 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 867 872 867 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 989 994 989 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 986 994 986 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 786 793 <span type="species:ncbi:9606">patient</span>
###xml 905 912 <span type="species:ncbi:9606">patient</span>
Snap-frozen biopsies from 109 patients collected prior to epirubicin (as preoperative therapy were investigated for TP53, CHEK2 and p14(ARF) mutations by sequencing the coding region and p14(ARF) promoter methylations. TP53 mutastions were associated with chemoresistance, defined as progressive disease on therapy (p = 0.0358; p = 0.0136 for mutations affecting p53 loop domains L2/L3). Germline CHEK2 mutations (n = 3) were associated with therapy resistance (p = 0.0226). Combined, mutations affecting either CHEK2 or TP53 strongly predicted therapy resistance (p = 0.0101; TP53 mutations restricted to the L2/L3 domains: p = 0.0032). Two patients progressing on therapy harbored the CHEK2 mutation, Arg95Ter, completely abrogating Chk2 protein dimerization and kinase activity. One patient (Epi132) revealed family cancer occurrence resembling families harboring CHEK2 mutations in general, the other patient (epi203) was non-conclusive. No mutation or promoter hypermethylation in p14(ARF) were detected.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 99 104 <span type="species:ncbi:9606">human</span>
This study is the first reporting an association between CHEK2 mutations and therapy resistance in human cancers and to document mutations in two genes acting direct up/down-stream to each other to cause therapy failure, emphasizing the need to investigate functional cascades in future studies.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 203 206 203 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-1">[1]</xref>
###xml 481 484 481 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Alba1">[2]</xref>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
Chemoresistance is the main obstacle to cure in most malignancies, including breast cancer. While adjuvant chemotherapy may reduce the hazard rate of relapse by about one third in breast cancer patients [1], the majority among patients harboring micro- metastases are not cured by today's standards. Considering patients harboring distant metastases, resistance and therapy failure inevitably occurs, in general over a time period of less than one year for each individual regimen [2].
###end p 9
###begin p 10
###xml 40 43 40 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning1">[3]</xref>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Knoop1">4</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Tanner1">5</xref>
###xml 392 395 392 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Thuerigen1">[6]</xref>
###xml 397 400 397 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hannemann1">[7]</xref>
###xml 402 405 402 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Sorlie1">[8]</xref>
###xml 601 604 601 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning2">[9]</xref>
###xml 609 613 609 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning3">[10]</xref>
Despite extensive experimental research [3], little data are available considering chemoresistance in vivo. For anthracycline therapy in breast cancer, topoisomerase-II amplifications have been associated with a dose-responsiveness different from what is observed in non-amplified tumors 4, 5. Several studies have tried to generate "prediction profiles" based on gene expression microarrays [6], [7], [8], however, none of the different profiles generated expressed a sensitivity suitable for clinical applications, or have been successfully reproduced by others (see references to original works in [9] and [10]).
###end p 10
###begin p 11
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Enoch1">[11]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Cho1">[12]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 504 508 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-KandiolerEckersberger1">[15]</xref>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bertheau1">[16]</xref>
p53 (the protein encoded by the TP53 gene) plays a key role in executing DNA-damage induced apoptosis and growth arrest [11]. Previously, our group reported mutations in the zink-binding domains L2 (codons 163-195) and L3 (codons 236-251) of p53 critical to DNA binding [12] to be associated with but not fully predictive for resistance to chemotherapy with a low-dose weekly anthracycline [13] or a mitomycin plus 5-fluoro-uracil containing [14] regimen. Similar findings were reported by another group [15]. In contrast, others reported TP53 mutations to predict sensitivity to a dose-dense epirubicin-cyclophosphamide regimen [16].
###end p 11
###begin p 12
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning1">[3]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Liu1">[17]</xref>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Buscemi1">[18]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chehab1">[19]</xref>
###xml 554 558 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hirao1">[20]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hirao2">[21]</xref>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Peters1">[22]</xref>
###xml 801 805 801 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Jallepalli1">[23]</xref>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 936 940 936 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bell1">[24]</xref>
###xml 993 998 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1096 1100 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Weischer1">[25]</xref>
###xml 1147 1152 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1236 1240 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen1">[26]</xref>
###xml 355 359 <span type="species:ncbi:10090">mice</span>
###xml 504 509 <span type="species:ncbi:10090">Mouse</span>
###xml 1174 1181 <span type="species:ncbi:9606">patient</span>
The finding that some tumors harboring wild-type TP53 may be resistant to anthracycline therapy lead us to postulate that other genes involved in the p53 pathway could be mutated in these tumors [3]. p53 is activated by post-translational modifications, and the protein is phosphorylated at multiple amino acids [17]. Phosphorylation at Ser 20 (Ser 23 in mice) by the Chk2 protein (coded by the CHEK2 gene) in response to DNA damage activates p53 by inhibiting binding to, and deactivation by, the MDM2 (Mouse Minute 2 homolog; HDM2) protein [18], [19], [20]. While experimental studies have suggested a critical role of Chk2 in activating p53 apoptotic response to genotoxic stress [21], [22], others claim Chk2 to be dispensable for p53 activation with respect to apoptosis as well as growth arrest [23]. Following an initial report of a CHEK2 germline mutation in a family filling the characteristics of a Li-Fraumeni syndrome (LFS) [24], recent papers have suggested germline mutations in CHEK2 to be associated with a moderately increased risk of breast and colon cancers (see references in [25]). Recently, we discovered a somatic, nonsense CHEK2 mutation in a single patient expressing resistance to doxorubicin low dose therapy [26].
###end p 12
###begin p 13
###xml 51 56 51 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 200 205 200 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Sharpless1">[27]</xref>
###xml 377 382 377 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bates1">[28]</xref>
###xml 528 533 528 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Christophorou1">[29]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Efeyan1">[30]</xref>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 500 505 <span type="species:ncbi:10090">mouse</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
A second mechanism of p53 activation is through p14(ARF) (p19 in mice) function. p14(ARF) does not phosphorylate p53, but inhibits MDM2 dependent p53 degradation through direct MDM2 binding. While p14(ARF)-mediated p53 activation has been linked to oncogene-induced p53 activation and, in general, considered not involved in response to DNA damage (see references in [27]), p14(ARF) may be activated through the E2F1/retinoblastoma pathway [28]. Importantly, two recent studies revealed lack of p19 (mouse homologue of human p14(ARF)) function in mice to inhibit p53 tumor suppressor function in response to ionizing radiation as well as DNA damaging agents [29], [30].
###end p 13
###begin p 14
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 455 460 455 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 452 460 452 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 487 492 487 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 484 492 484 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 532 540 532 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 575 580 575 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 645 650 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 658 663 658 663 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 655 663 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 693 704 693 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53, CHEK2</italic>
###xml 712 717 712 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 709 717 709 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 861 869 861 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 173 180 <span type="species:ncbi:9606">patient</span>
The aim of this study was 1) to explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen (90 mg/m2 body surface every 3 week) in patient with primary, locally advanced, breast cancer; 2) To explore defects in potential mechanisms activating p53 in response to DNA damage in breast cancer as a cause of drug resistance in wild-type tumors. To do so, we sequenced the complete coding regions for the CHEK2 and p14(ARF) genes and analyzed for p14(ARF) promoter hypermetylations; 3) Evaluate in vitro function of potential Chk2 and p14(ARF) protein translates corresponding to identified mutations in the CHEK2 and p14(ARF) genes; 4) Identify potential TP53, CHEK2 and p14(ARF) mutations to be germline, explore the incidence of different cancers among affected relatives with respect to specific mutations. By comparing in vitro characteristics of specific mutations to drug sensitivity and family cancer risk syndromes, this may add to our understanding of the importance of these gene cascades executing response to DNA damage versus tumor suppression activity.
###end p 14
###begin p 15
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 389 394 389 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 557 562 <span type="species:ncbi:9606">human</span>
Analyzing tumor samples from a total of 109 primary locally advanced breast cancer patients treated with epirubicin 90mg/3 weekly, we found TP53 mutations affecting the L2/L3 domains or protein dimerization, as well as non-functional CHEK2 mutations abrogating dimerization and phosphorylation, to be associated with therapy resistance; no mutation or promoter hypermethylations of the p14(ARF) gene was discovered. Our findings suggest a critical role for Chk2 with respect to DNA-damage-dependent p53 activation and resistance to anthracycline therapy in human breast cancer.
###end p 15
###begin title 16
Materials and Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Pivot1">[31]</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 395 402 <span type="species:ncbi:9606">patient</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
A total of 223 patients with locally advanced non-inflammatory breast cancer (T3-4 and/or N2) were randomly allocated to primary treatment either with epirubicin 90 mg/m2 or paclitaxel 200 mg/m2. The primary aim of the study was identification of markers predicting drug resistance to the regimens. Thus, the reason for randomizing patients was not for effect comparison, but to achieve similar patient cohorts in the two arms. Based on the findings of a clinical lack of cross-resistance between anthracyclines and taxane therapies in breast cancer [31], we hypothesized the mechanisms of resistance to be different between the two compounds. While the analysis of tumor samples from the paclitaxel is ongoing, we here report our findings from the patients allocated to the epirubicin arm.
###end p 18
###begin p 19
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 241 248 <span type="species:ncbi:9606">patient</span>
###xml 299 306 <span type="species:ncbi:9606">patient</span>
The epirubicin arm included a total of 109 patients (age 28 to 70 years, median 51 years). Two patients were analyzed for gene mutations but omitted from statistical analysis as protocol violators; histopathological examination revealed one patient (Epi089) to harbor a sarcomatoid tumor, while one patient Epi232 was erroneously enrolled with stage II disease.
###end p 19
###begin p 20
###xml 337 344 <span type="species:ncbi:9606">patient</span>
The study protocol was approved by the Regional Ethical Committee (Norwegian Health Region III), including formal Biobank registration in accordance to Norwegian law. The study and protocol is registered under the Norwegian Social Science Data services ((), University of Bergen project no 16297 and Helse Bergen project no 13025). Each patient gave written informed consent.
###end p 20
###begin title 21
Tissue Sampling
###end title 21
###begin p 22
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 37 44 <span type="species:ncbi:9606">patient</span>
Before commencing chemotherapy, each patient had an incisional tumor biopsy as described previously [14]. All tissue samples were snap-frozen immediately on removal in the theatre.
###end p 22
###begin title 23
Treatment Regime and Staging
###end title 23
###begin p 24
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 291 293 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hayward1">[32]</xref>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Therasse1">[33]</xref>
###xml 1095 1099 1091 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 1101 1105 1097 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 1278 1282 1274 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning4">[34]</xref>
###xml 395 403 <span type="species:ncbi:9606">patients</span>
###xml 1323 1330 <span type="species:ncbi:9606">patient</span>
Primary treatment consisted of epirubicin (90 mg/m2) administered as a 3-weekly schedule. Treatment was scheduled for four cycles unless progression occurred at an earlier stage. Clinical response was assessed before each treatment cycle, and the final response evaluated 3 weeks after the 4th cycle for overall response classification. Because the protocol was implemented by October 1997 with patients enrolled between November 1997 and December 2003, responses were consistently graded by the UICC system [32] and not the more recently implemented "RECIST" criteria [33]. Thus, responses were classified as CR (Complete Response, complete disappearance of all tumor lesions), PR (Partial Response, reduction >/=50% in the sum of all tumor lesions, calculated for each as the product of the largest diameter and the one perpendicular to it), PD (Progressive Disease, increase in the diameter product of any individual tumor lesion by >/=25%), and SD (Stable Disease, anything between PR and PD). To analyze for the predictive value of the different parameters, similar to our previous studies [13], [14] we compared PD tumors (non responders) with the combined group of tumors classified as SD/PR/CR (responders); the reason for this approach is discussed in detail elsewhere [34]. Median follow-up time was defined from patient inclusion in the study up to October 31, 2006. Deaths attributable to causes other than breast cancer were treated as censored observations.
###end p 24
###begin p 25
###xml 4 11 <span type="species:ncbi:9606">patient</span>
All patient records were subject to central audit for response classification (by E.L., B.O. and P.E.L.). Response classifications were completed and approved without any knowledge about result from laboratory analysis.
###end p 25
###begin title 26
RNA Purification
###end title 26
###begin p 27
###xml 217 218 213 214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Total RNA was purified by Trizol (Life Technologies, Inc.) extraction from snap-frozen tissue samples according to manufacturer's instructions. After extraction, the RNA was dissolved in 100 microl of DEPC treated ddH2O. cDNA was synthesized by reverse transcription using Transcriptor reverse transcriptase (Roche), according to the manufacturer's protocol.
###end p 27
###begin title 28
DNA Purification
###end title 28
###begin p 29
Genomic DNA from tumor biopsies and blood lymphocytes was isolated using QIAamp DNA Mini kit (Qiagen, Chatsworth, CA) according to the manufacturer's protocol.
###end p 29
###begin title 30
Mutation Analysis
###end title 30
###begin p 31
###xml 77 81 77 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 96 101 96 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 287 294 287 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t001">Table 1</xref>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 932 939 928 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t001">Table 1</xref>
All mutational analysis was performed blinded to clinical data. Mutations in TP53, CHEK2 and p14(ARF) genes were analyzed by PCR (or nested PCR) amplification and sequencing of PCR product, or by cloning of PCR products and sequencing of the resulting plasmids (all primers described in Table 1). Cloning was performed using the TOPO TA Cloning kit (Invitrogen). Sequencing of clones was performed until at least 10 different sequences covered all parts of the CHEK2 coding sequence. DNA sequencing was carried out directly on 1 microl PCR product or plasmid using Big Dye terminator mix (Applied Biosystems). Capillary gel electrophoresis, data collection, and sequence analysis were done on an automated DNA sequencer (ABI 3700). When a mutation was detected, the relevant exon was amplified by PCR from genomic tumor DNA and DNA from blood lymphocytes and sequenced for verification and germline detection. (Primers described in Table 1).
###end p 31
###begin title 32
PCR primers for amplification and sequencing of cDNA
###end title 32
###begin title 33
Loss of Heterozygosity (LOH)
###end title 33
###begin p 34
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hahn1">[35]</xref>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Jones1">[36]</xref>
###xml 699 703 699 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Skotheim1">[37]</xref>
###xml 691 698 <span type="species:ncbi:9606">patient</span>
Loss of heterozygosity (LOH) in tumors with mutations in CHEK2 was assessed using the microsatellite marker, D22S275, which maps to intron 4 of CHEK2. LOH in tumors with mutation in TP53 was assessed using two markers, one variable number tandem repeat in intron 1 [35] and a CA repeat close to the TP53 gene [36]. Fluorescently end-labeled primers were used in the PCR, and the PCR products were analyzed on an ABI 3700. LOH was evaluated by comparing the allele peak-height ratios from blood DNA and tumor DNA. A sample was scored as having AI (Allelic Imbalance) when a reduction in peak height of one allele in tumor sample was at least 18% compared with that of blood DNA from the same patient [37].
###end p 34
###begin title 35
###xml 15 20 15 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
Analysis of p14(ARF) promoter methylation
###end title 35
###begin p 36
###xml 333 334 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 408 415 400 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t001">Table 1</xref>
Genomic DNA was subjected to bisulphate conversion using the CpGenome DNA Modification Kit (Intergen) according to the manufacturer's protocol. Both the unmethylated- and methylated-specific PCRs were performed in 50 microl reaction mixes containing 2.5 U AmpliTaq Gold DNA Polymerase (Applied Biosystems), 1x PCR buffer, 1.5 mM MgCl2, 0.1 mM of each deoxynucleotide triphosphate, 0.2 microM of each primer (Table 1) and 2 microl of modified genomic DNA. Thermocycling conditions for both the unmethylated- and methylated-specific PCRs were an initial step of 5 minutes at 95degreesC followed by 35 cycles of 30 sec. at 94degreesC, 30 sec. at 60.5degreesC and 60 sec. at 72degreesC before a final elongation step at 72degreesC for 7 min.
###end p 36
###begin title 37
Chk2 Dimerisation
###end title 37
###begin p 38
Chk2 mutant's ability to form dimers with the wild-type protein was investigated by immunoprecipitation. U-2-OS cells were co-transfected with expression vectors expressing wild-type Chk2 with N-terminal Xpr-tag (pcDNA4/HisMax, Invitrogen) and mutated Chk2 forms with C-terminal V5-tag (pcDNA3.1/V5-His, Invitrogen). Transfection was performed using FuGene 6.0 transfection reagent (Roche) according to the manufacturer's instructions. Cells were harvested in lysisbuffer (50 mM TrisHCl pH 8.0, 150 mM NaCl, 0.5% NP40, 5 mM EDTA pH 8.0) 48 hours after transfection. An aliquote of the cell lysate was harvested for subsequent Chk2-mutant-V5 transfection verification. Samples were further incubated with A/G Pluss Agarose beads (Santa Cruz Biotechnology) at 4degreesC for 25 minutes before the beads were removed by centrifugation at 5000g for 4 minutes and the samples were incubated with 1.5 microg anti-V5 (Invitrogen) at 4degreesC for 90 minutes. Fresh A/G Pluss Agarose beads were added and the samples were incubated for another 90 minutes at 4degreesC. The beads were washed three times with 1xPBS, before being separated on a 10% polyacrylamide gel and blotted on to a nitrocellulose membrane. Chk2-wild-type-Xpr co-precipitated with Chk2-mutant-V5 was detected through incubations with anti-Xpr antibody (Invitrogen), HRP-conjugated secondary antibody and ECL detection reagent (GE Healthcare).
###end p 38
###begin title 39
Kinase Activity
###end title 39
###begin p 40
###xml 73 81 73 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 388 389 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 591 592 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 727 728 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1043 1044 1023 1024 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1055 1056 1035 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1157 1160 1125 1128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> 32</sup>
Chk2 mutant's ability to function as kinases was investigated through an in vitro kinase assay. The V5 expression vectors used for the dimerisation study were also used to express Chk2 mutants in the kinase assay. U-2-OS cells were transfected using the FuGene 6.0 transfection reagent (Roche) according to the manufacturer's instructions. Cells were then incubated at 37degreesC in 5% CO2 and humidified atmosphere. After 24 hours doxorubicin (Nycomed Pharma) was added to the media to a final concentration of 50ng/ml and the cells were further incubated for 24 hours before harvest. 75 cm2 of 90% confluent cells were harvested in 500 microl lysis buffer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 0.5% Triton X-100, 2 mM MgCl2, 5 mM EDTA), and the cytosol was incubated for 90 minutes at 4degreesC with 50 microl 50% Glutathione Sepharose beads (Amersham Biosciences) linked to anti-V5 antibody (Invitrogen). The beads were then washed twice with lysisbuffer containing 500 mM NaCl and twice with kinase assay buffer (50 mM HEPES, 10 mM MgCl2, 5 mM MnCl2, 2.5 mM EGTA). The beads received 30 microl kinase assay buffer with 7.5 microM cold ATP, 10 microCi 32P-gamma-ATP (GE Healthcare) and 2 microg isolated Cdc25C peptide, and was incubated at 30degreesC for 30 minutes. Samples were separated on a 12.5% polyacrylamide gel and blotted on to a nitrocellulose membrane. A radiosensitive imaging plate was exposed to the membrane and the plate was read in a FLA200 imager (Fuji).
###end p 40
###begin p 41
The kinase assay described above was also used to determine the Chk2 mutants' kinase activity after co-transfection of each Chk2 mutant and wild-type Chk2 in equal amounts.
###end p 41
###begin title 42
Statistical Analysis
###end title 42
###begin p 43
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Clantz1">[38]</xref>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 143 148 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 551 558 551 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t003">3</xref>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
Statistical analysis was performed using the Primer of Biostatistics system, version 5.0 [38]. The differences in the distribution of TP53 and CHEK2 mutations among patients revealing a PD and the responders were analyzed with use of Fisher's exact test. P-values are reported as accumulated two-sided. Because of the limited time of the follow-up, no formal statistical assessment of overall survival was performed. Relapse-free survival was analyzed by the log-rank test. Details regarding outcome in individual patients with mutations are shown in Table 2 and 3 to make them available to the reader.
###end p 43
###begin title 44
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Characteristics of TP53 mutants found and clinical data
###end title 44
###begin p 45
###xml 28 29 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 74 75 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 351 352 345 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 1018 1019 1010 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1218 1231 1210 1211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 759 766 <span type="species:ncbi:9606">patient</span>
###xml 870 877 <span type="species:ncbi:9606">patient</span>
###xml 1065 1072 <span type="species:ncbi:9606">patient</span>
###xml 1166 1173 <span type="species:ncbi:9606">patient</span>
degrees, Nucleotide number; 1, The bolded bases indicate the base change; 2, Functional predictions derived from a computer model that takes into account the 3D structure of wild-type and mutant proteins and is trained on the trans activation dataset from Kato et al. Mutations are classified as "functional" or "non-functional". More details here: ; a, Frequencies reported in IARC database () release October 2006. The frequencies are based on a total of 22822 reported mutations in all type of cancer and in 2274 reported mutations in breast cancer (brackets); T N M, TNM-classification, AJCC 2002 = UICC 2002, T, size or direct of the primary tumor; N, spread to regional lymph nodes; M, distant metastasis; ˆ, "F" followed by a number indicates that the patient was free of disease at that number of months of follow-up. "R" followed by a number indicates that the patient was alive at that number of months of follow-up but had suffered a relapse; (R), Site of relapse L, Locoregional; S, Skeletal; V; Visceral; *, "A" followed by a number indicates that the patient was alive at that number of months of follow-up. "D" followed by a number indicates that the patient died at that number of months of follow-up; double dagger, Characterized as a mutation affecting L2/L3 domain, since it leads to truncation of the protein and will mostly affect L2/L3 domain; AI, Allelic imbalance; NA, Not available; ND, not done; NI, Not informative.
###end p 45
###begin title 46
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Characteristics of CHEK2 mutants found and clinical data
###end title 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 700 701 700 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 241 248 <span type="species:ncbi:9606">patient</span>
###xml 352 359 <span type="species:ncbi:9606">patient</span>
###xml 483 490 <span type="species:ncbi:9606">patient</span>
###xml 584 591 <span type="species:ncbi:9606">patient</span>
###xml 708 715 <span type="species:ncbi:9606">patient</span>
1, The bolded bases indicate the base change; T N M, TNM-classification, AJCC 2002 = UICC 2002, T, size or direct of the primary tumor; N, spread to regional lymph nodes; M, distant metastasis; 3, "F" followed by a number indicates that the patient was free of disease at that number of months of follow-up. "R" followed by a number indicates that the patient was alive at that number of months of follow-up but had suffered a relapse; ˆ, "A" followed by a number indicates that the patient was alive at that number of months of follow-up. "D" followed by a number indicates that the patient died at that number of months of follow-up; AI, Allelic imbalance; NI, Not informative; NA, Not available. "*" This patient subsequently relapsed with distant metastases at 64 months.
###end p 47
###begin title 48
Results
###end title 48
###begin title 49
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
TP53 Mutations and Response to Therapy
###end title 49
###begin p 50
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 167 174 167 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 689 696 689 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 741 745 741 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Borresen1">[39]</xref>
###xml 766 770 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 772 776 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Aas1">[40]</xref>
###xml 1085 1089 1085 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Halazonetis1">[41]</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 826 833 <span type="species:ncbi:9606">patient</span>
The TP53 mutations identified in the tumors of the patients treated with epirubicin together with the clinical response to therapy and follow-up data are presented in Table 2. Somatic TP53 mutations were identified in 23 (21.5%) of the patients. Normal tissue (WBC) was available from 18 of these for germline characterization, revealing none of the mutations identified to be germline alterations. Of the 23 mutations detected, 20 were missense and 3 were nonsense. One mutation (del483CAT) has not been reported previously either in breast cancer or in any other tumor type (IARC database: ). Twelve of the mutations directly or indirectly affected the L2/L3 domains of the p53 protein (Table 2) previous found to predict a poor prognosis [39] and drug resistance [14], [40]. For statistical comparison, mutation Gly325Ter (patient Epi215) located to the tetramerization domain is grouped together with the mutations affecting the L2/L3 domain, since this mutation leads to truncation of the protein and with loss of tetramerization and functional defects similar to L2/L3 mutations [41].
###end p 50
###begin p 51
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t004">Table 4</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
There was a statistical significant correlation between TP53 mutation status and lack of treatment response (PD) (Table 4; p = 0.0358; Fisher exact test). When tumors harboring TP53 mutations affecting the p53 L2/L3 DNA-binding domains were compared to those with wild-type TP53 or TP53 mutations outside the L2/L3 domains, this correlation was further strengthened (p = 0.0136).
###end p 51
###begin title 52
Clinical response in relation to different parameters
###end title 52
###begin p 53
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sup>
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sup>1</sup></italic>
P1 with regard to clinical response comparing CR+PR+SD versus PD
###end p 53
###begin p 54
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sup>2</sup></italic>
P2 with regard to clinical response comparing CR+PR versus PD
###end p 54
###begin p 55
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
One of the PD patients has got a mutation both in CHEK2 and TP53 (L2 domain), this has been taken into consideration under calculation of statistical significance
###end p 55
###begin p 56
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 130 131 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
P, with regard to clinical response comparing CR+PR versus PD; 2P, with regard to clinical response comparing CR+PR+SD versus PD; *, One of the PD patients has got a mutation both in CHEK2 and TP53 (L2 domain), this has been taken into consideration under calculation of statistical significance.
###end p 56
###begin p 57
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 53 57 53 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-HernandezBoussard1">[42]</xref>
###xml 217 221 217 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The previously described TP53 polymorphism, Arg72Pro [42] was detected in 31 (29%) of our patients. No correlation was found between this polymorphism and lack of treatment response (p = 0.2750; Fisher exact test) or TP53 mutational status (p = 0.2024).
###end p 57
###begin title 58
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
CHEK2 Mutations and Response to Therapy
###end title 58
###begin p 59
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t003">Table 3</xref>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 714 719 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 809 814 809 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1021 1026 1021 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1199 1204 1199 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 274 281 <span type="species:ncbi:9606">patient</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 854 862 <span type="species:ncbi:9606">patients</span>
###xml 997 1004 <span type="species:ncbi:9606">patient</span>
###xml 1037 1044 <span type="species:ncbi:9606">patient</span>
Table 3 presents the patients with detected CHEK2 mutations together with a description of the clinical response and follow up-data. CHEK2 mutations were identified in three out of the 109 patients (2.8%). Notably, each of the CHEK2 mutations identified was also present in patient lymphocyte DNA, confirming a germline origin. The Arg95Ter (C283T) mutation is novel. This mutation was present in two patients (Epi132 and Epi203) living in different parts of Norway with no known family relationship. However, linkage analysis using microsatellite markers (D22S275, D22S272, D22S1172 and D22S423) suggested a common founder mutation (data not shown). The C283T transition generates a novel stop codon in exon 1 of CHEK2, leading to truncation of the Chk2 protein. LOH analysis indicated loss of the wild-type CHEK2 allele in the both tumors from the two patients harboring this mutation (Epi132 and Epi203). Both these tumors were non-responsive to epirubicin therapy (PD). In contrast, the third patient with a germline CHEK2 mutation (patient Epi151; point mutation at T1091C, Ile364Thr) had a partial response to epirubicin therapy. This tumor was non-informative with respect to LOH. Taking all CHEK2 mutations together, they predicted resistance to epirubicin (p = 0.0226).
###end p 59
###begin p 60
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bell1">[24]</xref>
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Reddy1">[43]</xref>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
The previously described silent Glu84Glu (A252G) polymorphism [24], [43] in exon 1 was detected in two (1.9%) patients. No association between this polymorphism and treatment response was recorded.
###end p 60
###begin p 61
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 167 174 167 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 261 268 261 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 284 288 284 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 604 611 604 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 649 654 649 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 661 665 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 834 838 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen1">[26]</xref>
###xml 865 870 865 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 965 969 965 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen1">[26]</xref>
###xml 1171 1179 1171 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1230 1237 1230 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1278 1282 1278 1282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen1">[26]</xref>
###xml 1304 1309 1304 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1463 1467 1463 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1491 1496 1491 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1543 1547 1543 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1575 1580 1575 1580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 328 335 <span type="species:ncbi:9606">patient</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 676 683 <span type="species:ncbi:9606">patient</span>
###xml 933 941 <span type="species:ncbi:9606">patients</span>
###xml 1437 1444 <span type="species:ncbi:9606">patient</span>
###xml 1524 1532 <span type="species:ncbi:9606">patients</span>
One of the tumors (Epi203) harboring the C283T substitution (Arg95Ter) also harbored a somatic TP53 mutation in codon 175, Arg175His, located in the L2 domain of p53 (Table 2). This mutation was detected in another four of our patients treated with epirubicin (Table 2). In addition, TP53 Arg175His mutation was recorded in one patient of our previous study evaluating response to doxorubicin [13]. The fact that none of the Arg175His patients presented here or in our previous study revealed resistance to therapy (PD) suggests this mutation may not cause resistance to anthracyclines in breast cancers in vivo. Omitting the tumor harboring both a CHEK2 and a TP53 mutation (patient Epi203) from statistical analysis, Chk2 mutations (n = 2) were non-significantly associated with therapy resistance (p = 0.1633). In a previous study [26], however, we analyzed for CHEK2 mutation status in relation to therapy outcome in a cohort of patients from doxorubicin study [13]. In that study [26], we detected the previously identified mutation Ile157Thr. In addition, we detected a novel nonsense somatic mutation (1368InsA). This mutation was associated with lack of function in vitro; moreover, it was associated with drug resistance in vivo. Analyzing our material and this cohort [26] together, (n = 160), CHEK2 mutations (n = 5 in total) predicted for resistance to doxorubicin and epirubicin therapy (p = 0.0123). Even though, excluding patient Epi203 (harboring TP53 Arg175His and Arg95Ter CHEK2 mutation) as well as other patients harboring TP53 L2/L3 mutations (n = 129), CHEK2 mutations (n = 4 in total) predicted for resistance to doxorubicin and epirubicin therapy (p = 0.030).
###end p 61
###begin title 62
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
TP53 and CHEK2 Mutations Combined and Response to Therapy
###end title 62
###begin p 63
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 182 187 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 191 195 191 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 235 236 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP</italic>
###xml 659 666 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t004">Table 4</xref>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
Assuming that TP53 and CHEK2 mutations may substitute for each other, we analyzed for the predictive effect of mutations in both genes. The occurrence of a mutation affecting either CHEK2 or TP53 strongly predicted therapy resistance (p = 0.0101; Fisher exact test). When tumors harboring TP53-L2/L3 mutations and CHEK2 mutations were compared with those wild-type or TP53 mutations outside the L2/L3 domain, the correlation was further strengthened (p = 0.0032; Fisher exact test). The significance was preserved when comparing patients with a PD to objective responders (CR and PR) excluding patients with stable disease (SD) from the statistical analysis (Table 4).
###end p 63
###begin title 64
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
p14(ARF) Mutations and Promoter Methylations
###end title 64
###begin p 65
###xml 63 68 63 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Neither mutations nor polymorphisms in the coding region of p14(ARF) were observed among the 107 patients analyzed. Likewise, no promoter methylations were detected.
###end p 65
###begin title 66
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Influence of CHEK2 and TP53 Mutation Status on Relapse-Free Survival
###end title 66
###begin p 67
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t003">3</xref>
###xml 292 300 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g001">Figure 1</xref>
###xml 303 312 303 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g001">Figure 1A</xref>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 372 377 372 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 567 571 567 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 671 680 671 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g001">Figure 1B</xref>
###xml 743 748 743 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 906 910 906 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 915 920 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1000 1009 1000 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g001">Figure 1C</xref>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
Because of the limited time of the follow-up, no formal statistical assessment of overall survival was performed. Details regarding outcome for individual patients with mutations are described in Table 2 and 3 to make these data available to the reader. Relapse-free survival is depicted in (Figure 1). Figure 1A shows relapse-free survival for the patients with TP53 and CHEK2 mutations (all mutations found) compared to patients without any TP53 or CHEK2 mutations, no difference in relapse-free survival was observed. Similar, no difference was seen when grouping TP53 mutations outside L2/L3 and CHEK2 mutation not affecting kinase function (Ile364Thr) as wild-type (Figure 1B). Grouping tumors harboring a mutation in L2/L3 together with CHEK2 mutations affecting kinase domain (Arg95Ter) in one group, mutations outside TP53 L2/L3 and Ile364Thr as one group and tumors without any found mutations in TP53 and CHEK2 separately, again no noticeably difference in relapse-free survival were seen (Figure 1C). Notably, in addition to a short median follow-up time, a total of 35 patients with a sub-optimal response to epirubicin received subsequent treatment with paclitaxel, which may have influenced the outcome.
###end p 67
###begin title 68
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Kaplan-Meyer analysis of the relapse-free survival of the patients according to mutations.
###end title 68
###begin p 69
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 81 86 81 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 103 107 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 254 259 254 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 423 430 <span type="species:ncbi:9606">patient</span>
WT, wild-type; TP53+CHEK2 mut, all found mutations in TP53 and CHEK2; TP53 L2/L3+CHEK2 (Arg95Ter) mut, TP53 mutations affection L2/L3 domain and CHEK2 mutations affecting kinase function; TP53+CHEK2 (Ile364Thr), mutations not affecting L2/L3 domains and CHEK2 mutations not affecting kinase function. Deaths due to causes other than breast cancer are treated as censored observations. Each "+" mark represents the time one patient was censored. NS, Non significant.
###end p 69
###begin title 70
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
CHEK2 Mutant's Capability to Form Dimers
###end title 70
###begin p 71
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 305 310 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 552 560 552 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g002">Figure 2</xref>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
To investigate whether the identified CHEK2 mutations affect the ability of the Chk2 protein to form dimers, co-transfection and immunopresipitation of V5-tagged mutants and Xpress-tagged wild-type Chk2 were performed using CHEK2 low-expressing U-2-OS cells. As we identified the previously characterized CHEK2 germline mutants variants Arg117His (n = 2 and Ile157Thr (n = 1) among patients allocated to primary treatment with paclitaxel in our ongoing study, these mutants were evaluated together with Arg95Ter and Ile364Thr. The results presented in Figure 2 show that all Chk2 variants carrying a point mutation were able to form dimers with wild-type Chk2, whereas the Arg95Ter variant was not.
###end p 71
###begin title 72
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Pulldown-assay for CHEK2 mutants.
###end title 72
###begin p 73
V5-tagged Chk2 mutants were co-expressed with Xpr-tagged wt-Chk2 in U-2-OS-cells and immunoprecipitation was performed using anti-V5 antibody. Expression of the Chk2 mutants was monitored by anti-V5 based Western blot analysis prior to immunoprecipitation (upper panel). The Chk2 mutant's ability to dimerize with the wild-type protein was detected by anti-Xpr Western blot analysis of the precipitate (lower panel).
###end p 73
###begin title 74
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Kinase Activity of CHEK2 Mutants
###end title 74
###begin p 75
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 95 103 95 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chehab2">[44]</xref>
###xml 531 535 531 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chehab2">[44]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Falck1">[45]</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Falck2">[46]</xref>
To investigate whether the identified CHEK2 mutants retained the wild-type kinase activity, an in vitro Chk2 kinase assay with respect to Chk2 autophosphorylation and Cdc25 substrate phosphorylation was performed. The U-2-OS cells were preferred for this assay because they were previously found to express only low levels of endogenous Chk2 [44]. This was confirmed by us using an antibody recognizing endogenous protein (data not shown). These cells have previously been used by other investigators to study Chk2 kinase activity [44], [45], [46].
###end p 75
###begin p 76
###xml 67 75 67 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Wu1">[47]</xref>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 380 388 380 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figure 3</xref>
###xml 659 663 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Wu1">[47]</xref>
###xml 849 857 849 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figure 3</xref>
The two mutants Arg117Gly and Ile157Thr were previously tested for in vitro kinase activity [47], but were both included here, together with wild-type CHEK2 as controls. Compared to wild-type Chk2, the Ile157Thr mutant retained wild-type kinase activity. The mutant Ile364Thr showed partially reduced kinase activity both in term of Cdc25-phosphorylation and autophosphorylation (Figure 3). In contrast, the mutant Arg117Gly showed strongly reduced kinase activity while the Arg95Ter mutant was totally devoid of any Chk2 kinase activity. The activity recorded for Ile157Thr and Arg117Gly was consistent with previously reported results for these two mutants [47]. Notably, there was an internal consistency with respect to percentage activity reduction comparing individual mutants with respect to autophosphorylation and phosphorylation of Cdc25 (Figure 3).
###end p 76
###begin title 77
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Kinase activity of CHEK2 mutants.
###end title 77
###begin p 78
###xml 179 187 179 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 387 403 387 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figures 3A and B</xref>
A) Level of Chk2 mutants immunoprecipitated from U-2-OS cells, used as input for kinase activity assay, monitored by anti-V5 based Western blot analysis. B) Autoradiogram showing in vitro kinase activity of Chk2 mutants with respect to both Chk2 autophosphorylation and Cdc25 phosphorylation. C) Kinase activity of CHEK2 mutants normalized for kinase-input, based on band intensities in Figures 3A and B.
###end p 78
###begin p 79
###xml 366 387 366 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Materials and Methods</xref>
###xml 441 449 441 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g004">Figure 4</xref>
###xml 507 515 507 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figure 3</xref>
Since enzymatically active Chk2 exists as dimers, it was important to determine the effect of Chk2 mutants on wild-type/mutant heterodimer kinase activity. The effect on Chk2 kinase activities (Chk2 autophosphorylation and Cdc25 substrate phosphorylation) of the individual mutants were therefore determined after co-transfection with wild-type Chk2 as described in Materials and Methods. The results from this co-transfection-kinase assay (Figure 4) were similar to those of the single-transfection assay (Figure 3) except in the case of the Arg117Gly mutant, which expressed a substantial kinase activity when complexed with wild-type Chk2. This is consistent with previous data indicating that the Arg117Gly mutant has neglectable kinase activity itself but dimerizes efficiently to Chk2 wild-type without strongly affecting the wild-type Chk2 activity. Hence, the activity detected is probably caused by the co-transfected and co-precipitated wild-type protein.
###end p 79
###begin title 80
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Kinase activity of CHEK2 mutant's co-transfected with CHEK2 wild-type.
###end title 80
###begin p 81
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
A) Kinase assay input of V5-tagged mutant Chk2 and Xpr-tagged wild-type Chk2, monitored by anti-V5 and anti-Xpr based Western blot analysis. B) Autoradiogram showing in vitro kinase activity (Chk2 autophosphorylation and Cdc25 phosphorylation) of Chk2 mutants with co-precipitated Chk2 wild-type.
###end p 81
###begin p 82
###xml 130 138 130 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g004">Figure 4</xref>
###xml 374 382 374 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g005">Figure 5</xref>
To rule out the possibility that endogenously expressed wild-type Chk2 contributed to observed Arg117Gly kinase activity shown in Figure 4, we compared the Arg117Gly variant activity in the presence or absence of co-transfected wild-type Chk2 to the activities of Arg95Ter under the same conditions. The Arg95Ter variant does not form dimers with wild-type Chk2. As seen in Figure 5, Arg117Gly, which forms dimers with Chk2 wild-type, allows increased activity when co-transfected with wild-type as compared to the corresponding activity for the Arg95Ter mutant. The fact that Arg117Gly, when transfected alone, displays very similar activity as Arg95Ter or negative control (background levels), strongly indicates that the contribution of endogenous Chk2, which, similarly to exogenously expressed wild-type Chk2 co-precipitate with Arg117Gly is non-significant.
###end p 82
###begin title 83
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Contribution of co-precipitated Chk2 wild-type to the activity in the in vitro assays.
###end title 83
###begin p 84
Transfection of the Arg117Gly mutant with and without Chk2 wild-type, along with Arg95Ter +/- wild-type. Arg117Gly, when transfected alone, does not display higher kinase activity (Cdc25 phosphorylation) than Arg95Ter or negative control. This strongly indicates that the contribution of endogenous Chk2 is non-significant.
###end p 84
###begin title 85
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Family Cancer Incidence in Relation to CHEK2 Germline Mutations
###end title 85
###begin p 86
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bell1">[24]</xref>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Varley1">[48]</xref>
###xml 717 722 717 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 777 785 777 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g006">Figure 6</xref>
###xml 506 513 <span type="species:ncbi:9606">patient</span>
###xml 688 695 <span type="species:ncbi:9606">patient</span>
Following an initial report of a family with a CHEK2 germline mutation expressing an increased cancer incidence resembling the Li-Fraumeni syndrome [24], recent studies have revealed the more common CHEK2 mutations to be associated with a moderately increased risk of breast and colorectal cancers. We hypothesized that CHEK2 mutations having a detrimental effect on drug sensitivity could be associated with a more aggressive, Li-Fraumeni or a Li-Fraumeni-like (LFL) cancer syndrome [48]. Except from the patient harboring the Ile364Thr mutation who did not have any known congestion of cancer disease in the family, a detailed assessment of family cancer history was performed for each patient harboring a germline CHEK2 mutation. The family cancer pedigrees are depicted in Figure 6.
###end p 86
###begin title 87
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Pedigrees of the breast cancer cases with germline mutations in CHEK2.
###end title 87
###begin p 88
###xml 79 87 <span type="species:ncbi:9606">patients</span>
The index individuals initially screened are indicated with arrows. All cancer patients marked in bold, and cancers are indicated by type and age at diagnosis. D followed by number indicates the age of death. #, indicate that diagnosis could not be verified from medical documents. Mut -, indicates individuals tested negative for relevant mutations. Mut +, indicates that individuals hold the relevant mutation. The trees have been altered to preserve anonymity, but the meaning of the report is not affected by these alterations. BC, Breast cancer; BD, Blood disease; BLC, Bladder cancer; CC, Colon cancer; EC, Endometri cancer; GC, Gastric cancer; HD, Heart disease; HL, Hodgkins Lymphoma; L, Lymphoma; LAC, Larynx cancer; LC, Lung cancer; LE, Leukemia; LEC, Liver cancer; OC, Ovarian cancer; OL, Oral Lymphoma M; P, Parkinson; PC, Prostate cancer; SA, Sarcoma; SE, Seminom; SI, Carcinoid in small intestine; TBC, Tuberculosis.
###end p 88
###begin p 89
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 750 755 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 781 785 781 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Weischer1">[25]</xref>
###xml 6 14 <span type="species:ncbi:9606">patients</span>
While patients harboring CHEK2 germline mutations revealed different types of cancers (mainly breast and tumors of the gastrointestinal area) in their family, surprisingly, no distinct pattern discriminating families harboring the Arg95Ter mutation from the other CHEK2 mutated families could be identified. One of them (Epi203), who inherited the mutation from her father's side of the family, had no accumulation of either breast or colorectal cancer on that side. It should be noted, however, that two brothers of her fathers mother had prostate cancer, and two siblings of his father having hepatocellular carcinoma and bladder cancer, respectively), while the other expressed a disease pattern resembling what has been seen with the more common CHEK2 mutations, like del1100C [25].
###end p 89
###begin title 90
Discussion
###end title 90
###begin p 91
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lee1">[49]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Vousden1">[50]</xref>
TP53 plays a key role as a tumor suppressor gene. Its protein product activates processes such as growth arrest, DNA repair, apoptosis and/or senescence in response to genotoxic damage as well as oncogene activity [49], [50]. Despite being extensively studied, critical issues regarding regulation of the p53 protein remain poorly understood, and conflicting evidence obtained in different experimental systems make the clinical relevance of experimental data questionable.
###end p 91
###begin p 92
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 246 250 246 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 520 524 520 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 549 554 549 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 546 554 546 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 705 709 705 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 841 846 841 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 900 908 900 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1067 1070 1067 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14</italic>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
Chemoresistance is the main obstacle to cancer cure in most malignancies, including breast cancer. Previously, we found TP53 mutations affecting the L2/L3 DNA binding domain to be associated with lack of responsiveness to doxorubicin monotherapy [13] as well as mitomycin and 5-fluoro-uracil in concert [14]. However, some tumors revealed therapy resistance despite harboring wild-type TP53. Postulating that these tumors may harbor genetic disturbances in genes playing a key role in the p53 pathway, we here sequenced TP53 along with CHEK2 and p14(ARF), the latter two known to play a critical role as p53 activators, in tumors from 109 patients treated with epirubicin monotherapy. Our results confirm TP53 mutations, in particular those affecting the L2/L3 domains, to be associated with drug resistance. Most importantly, we also found CHEK2 mutations generating a non-functional protein in our in vitro assays to be associated with drug resistance. In contrast, none of our tumors harbored either mutations or expressed promoter hypermethylations affecting the p14.
###end p 92
###begin p 93
###xml 9 17 9 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 475 483 475 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figure 3</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g004">4</xref>
###xml 850 858 850 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g003">Figure 3</xref>
###xml 863 864 863 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g005">5</xref>
Based on in vitro assays, we were able to classify the different Chk2 mutants with respect to dimerization capability as well as kinase activity (Chk2 autophosphorylation and Cdc25 substrate phosphorylation). In addition, the kinase activities of the Chk2 wild-type/mutant complexes were monitored in co-transfection experiments. Notably, each point mutation (except for Arg117Gly) revealed similar relative kinase efficacy whether co-transfected with wild-type Chk2 or not (Figure 3 and 4). Cells co-transfected with Arg117Gly and wild-type Chk2 revealed kinase activity, probably due to the contribution of the wild type protein in Chk2 mutant - wild-type heterodimers. In contrast, cells transfected with Arg95Ter revealed no kinase activity whether co-transfected with wild-type Chk2 or not, clearly distinguishing this mutation from the others (Figure 3 and 5).
###end p 93
###begin p 94
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chehab2">[44]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Falck1">[45]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Falck2">[46]</xref>
###xml 846 854 846 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g005">Figure 5</xref>
All in vitro assays were based on transfection of the U-2-OS cell line, a cell line known to express wild-type Chk2 at low levels, and previously used by other investigators to study Chk2 activity [44], [45], [46]. Since we were not able to obtain satisfactory technical quality of the kinase assay in cell lines negative for Chk2 (HCT 15 and HCT 116), we assessed potential background kinase activity due to endogenous Chk2 by performing western blot analysis revealing the endogenous levels of Chk2 in U-2-OS cells to be non-significant compared to the exogenously expressed Chk2 levels (data not shown). We also performed a separate kinase assay, directly comparing the effect of binding partners for the dimerizing Arg117Gly and the non-dimerizing Arg95Ter. This assay also revealed the contribution of endogenous Chk2 to be non-significant (Figure 5).
###end p 94
###begin p 95
###xml 11 19 11 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 523 530 523 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 792 797 792 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 239 246 <span type="species:ncbi:9606">patient</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
Taking our in vitro findings together with in vivo observations, our present data confirm that the functionally defective CHEK2 Arg95Ter mutation, together with LOH, is associated with resistance to anthracycline therapy. In contrast, the patient harboring the Ile364Thr mutation, moderately reducing phosphorylation activity, responded well to therapy. The other missense mutations; Arg117Gly and Ile157Thr were observed among patients receiving paclitaxel therapy only; thus, their influence on anthracycline sensitivity in vivo could not be addressed. Yet, based on the finding that the Arg117Gly mutant expressed no intrinsic activity, but readily dimerized to the wild-type protein without abolishing its activity, we hypothesize that this mutation and, probably, other yet unidentified CHEK2 mutations with a similar lack of intrinsic kinase activity, may cause resistance to anthracycline therapy if combined with LOH in breast cancer.
###end p 95
###begin p 96
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 381 386 381 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(ARF)</sup>
###xml 378 386 378 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p14<sup>(ARF)</sup></italic>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Toledo1">[51]</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Shiloh1">[52]</xref>
###xml 970 974 970 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Gurley1">[53]</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Jallepalli1">[23]</xref>
###xml 1107 1115 1107 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1115 1119 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Hirao2">[21]</xref>
###xml 1213 1217 1213 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chehab1">[19]</xref>
###xml 1360 1364 1360 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Toledo1">[51]</xref>
###xml 1508 1512 1508 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bartek1">[54]</xref>
###xml 1636 1641 1636 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
Our present findings have two major implications. First, we confirm that mutations in genes encoding proteins located within the same functional pathway may substitute for each other with respect to drug sensitivity, revealing for the first time a functional pathway critical to chemotherapy response in vivo. Second, the identification of mutations in the CHEK2 but not in the p14(ARF) gene in resistant tumors suggests that Chk2 mediated phosphorylation of p53 is a critical event in executing anti-tumor effect as a response to DNA damaging agents in breast cancer. This adds to our understanding not only of the function of p53 but Chk2 as well. p53 undergoes phosphorylation at multiple sites by different kinases, including Chk2 [51]. While activation of the ATM leading to direct (Ser 15) and Chk2-mediated (Ser 20) phosphorylation of p53 is considered an important mechanism for triggering p53 activation in response to DNA damage [52], some reports suggest ATM [53] and even Chk2 [23] to be redundant to this function. Importantly, Chk2 has been shown capable of inducing ATM-independent apoptosis in vitro[21]. While Chk2 phosphorylates p53 at Ser 20, thereby stabilizing p53 by preventing MDM2 binding [19], Chk2 also phosphorylates p53 at six additional sites, including Ser 313 and Ser 314 located in the nuclear localization signal domain of p53 [51]. In addition, Chk2 phosphorylates other important targets like BRCA1, Cdc25A and Cdc25C involved in DNA repair, G1 and G2 arrest, respectively [54]. Despite the wide range of known Chk2 substrates relevant for DNA repair and cell cycle control, our present findings that CHEK2 mutations leading to non-functional Chk2 protein may substitute for p53 mutations strongly advocate a role for Chk2 with respect to drug sensitivity executed through p53 activation.
###end p 96
###begin p 97
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 168 175 168 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003062-t002">Table 2</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 605 610 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen1">[26]</xref>
###xml 944 948 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Ryan1">[55]</xref>
###xml 1057 1061 1057 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Tsang1">[56]</xref>
###xml 1153 1160 1153 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1302 1306 1302 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Moll1">[57]</xref>
###xml 1437 1441 1437 1441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Speidel1">[58]</xref>
###xml 1529 1533 1529 1533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Sullivan1">[59]</xref>
###xml 1653 1658 1653 1658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 2034 2038 2034 2038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Staalesen2">[60]</xref>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 274 281 <span type="species:ncbi:9606">patient</span>
###xml 419 427 <span type="species:ncbi:9606">patients</span>
###xml 546 553 <span type="species:ncbi:9606">patient</span>
Notably, one of the tumors (Epi203) with the Arg95Ter CHEK2 mutation in addition harbored a somatic TP53 mutation, Arg175His, with allelic imbalance for the TP53 gene (Table 2). Importantly, among another four patients in this study (Epi063, Epi071, Epi087, Epi153) and one patient from our previous doxorubicin protocol [13] harboring the Arg175His mutation together with allelic imbalance for TP53, all five of these patients responded to anthracycline therapy either with a partial response or stable disease. In contrast, Epi132 and the only patient for whom we previously identified a non-functional CHEK2 mutation (1368InsA; coding for a non-functional protein translate with cytoplasmic location [26]) expressed resistance to epirubicin and doxorubicin, respectively. Arg175His is a p53 "hot-spot" structural mutation reported to have defects with respect to transcriptional activation and also to negatively interact with wild-type p53 [55]. While this mutation has been shown to enhance chemoresistance upon transfection into p53 null Saos-2 cells [56], these osteosarcoma-derived cells may not necessarily be representative for breast cancers in vivo. Recent evidence strongly support p53 to be involved also in non-transcriptional mediated apoptosis by interacting with the Bcl-2/Bax system [57], and transcription-defect structural p53 mutants have been shown to execute non-transcriptional apoptosis in experimental systems [58]. Concomitant inactivation of Chk2 and p53 in breast cancer has been recorded by others [59], and the finding that a somatic mutation may generate a "growth advantage" in tumor cells already harboring a germline CHEK2 mutation may not implicate an effect on drug sensitivity in tumors not yet exposed to cytotoxic compounds. Rather, it may indicate a growth advantage, probably related to loss of p21 function. Notably, in a previous study we found the p21 polymorphism G251A to be associated with an increased risk of developing large breast cancers but to have no effect on drug sensitivity [60], indicating that growth rate and drug resistance may be regulated independently. Taken together, we believe our findings advocate a role for Chk2 in executing cellular response to anthracycline-induced DNA damage.
###end p 97
###begin p 98
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
As mentioned above, removing TP53 mutated tumors including the double-mutated Epi203 from statistical analysis, CHEK2 mutation status still predicted for resistance to anthracycline therapy. In addition, removing the tumors harboring the Arg175His mutation from the p53 "L2/L3" group strengthened the correlation to lack of treatment response to epirubicin (p = 0.0005).
###end p 98
###begin p 99
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler1">[13]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 626 630 626 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 700 703 700 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning1">[3]</xref>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bartek1">[54]</xref>
###xml 963 967 963 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Stevens1">[61]</xref>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
###xml 484 491 <span type="species:ncbi:9606">patient</span>
Comparing the effects of mutations in the CHEK2 gene to TP53 mutations indirectly underlines the importance of the role of Chk2 to chemoresistance. Our present findings as well as results from our previous studies [13], [14] revealed that about 50% of the patients with tumors harboring TP53 L2/L3 mutations to be non-responders to primary therapy. In contrast, all our three patients harboring a non-functional CHEK2 mutation (the two Arg95Ter mutated patients here and our previous patient harboring the 1368InsA) expressed primary resistance to therapy. We previously hypothesized that therapy response in tumors harboring TP53 L2/L3 mutations could be due to redundant pathways acting in concert [3]. Although no definite conclusion should be drawn from a limited number of observation, the fact that Chk2 not only phosphorylates p53 but also phosphorylates other substrates such as Cdc25A and Cdc25C [54] and E2F1 in response to etoposide-induced DNA damage [61] may indicate that inactivation of redundant pathways could take place in parallel.
###end p 99
###begin p 100
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Cho1">[12]</xref>
###xml 434 435 434 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 205 212 <span type="species:ncbi:9606">patient</span>
###xml 278 285 <span type="species:ncbi:9606">patient</span>
The literature remains inconsistent with respect to whether the border amino acids 163, 195, 236 and 251 should be included in the p53 L2 and L3 domains [12]. Taking a conservative approach, we classified patient Epi56, harboring a mutation in codon 163, as a L2/L3 mutant. The patient harboring this mutation responded to therapy (PR). If this mutation was classified as outside the L2 domain, our p-value had been strengthened from p = 0.0136 to p = 0.0096.
###end p 100
###begin p 101
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Varley1">[48]</xref>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Berns1">[62]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bergh1">[63]</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Brresen1">[64]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Geisler2">[14]</xref>
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Aas1">[40]</xref>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bell2">[65]</xref>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 829 833 829 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Evans1">[66]</xref>
###xml 1207 1213 1207 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003062-g006">Fig. 6</xref>
###xml 1222 1227 1222 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 1238 1242 1238 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
###xml 1087 1094 <span type="species:ncbi:9606">patient</span>
Germline mutations in TP53 cause the Li-Fraumeni and Li-Fraumeni-like cancer disposition syndromes. However, while the germline and somatic mutations associated with these syndromes reveal a preference for the same codons [48], TP53 mutations affecting the DNA-binding domains seem associated with a poor prognosis [62], [63], [64] and, in particular, drug resistance [14], [40] in breast cancer. Thus, tumor suppression and tumor cell response to chemotherapeutics may involve different parts of p53 protein function. Following an initial report identifying a CHEK2 mutation in a family expressing characteristics of the Li-Fraumeni syndrome [65], recent evidence has linked CHEK2 founder mutations to a moderately increased risk of breast- and colorectal cancers with some additional disposition for other malignancies as well [66]. However, cancer incidence and phenotypes did not reveal an aggressive Li-Fraumeni or Li-Fraumeni-like tumor pattern. Similar to the two patients in our paclitaxel treatment arm harboring the rare but previously characterized mutation Arg117Gly and the patient with the Ile157Thr mutation, they expressed a moderately increased risk of breast and gastrointestinal cancers (Fig. 6). Thus, CHEK2 resembles TP53 in as much as there seems to be no direct correlation between effects of individual mutations with respect to tumor suppression and drug resistance.
###end p 101
###begin p 102
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Puma</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Noxa</italic>
###xml 292 295 292 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bax</italic>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Ryan1">[55]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Villunger1">[67]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Nister1">[68]</xref>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Moll1">[57]</xref>
###xml 550 554 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chipuk1">[69]</xref>
###xml 717 721 717 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chipuk2">[70]</xref>
###xml 894 898 894 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Chen1">[71]</xref>
###xml 931 935 931 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Krajewski1">[72]</xref>
###xml 1354 1361 1354 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 267 271 <span type="species:ncbi:9696">Puma</span>
Our finding that TP53 mutations located to the DNA-binding domains predicts drug resistance may indicate transcriptional mechanisms to be involved in drug-induced cell death. p53 induced apoptosis has been associated with transcriptional induction of genes including Puma and Noxa as well as Bax in experimental systems [55], [67], [68]. Yet, recent evidence has revealed p53 to induce apoptosis through non-transcriptional mechanisms by direct protein interactions with members of the Bcl-2/Bax system and mitochondrial release of cytochrom c [57], [69]. In deed, there is evidence that the DNA-binding domains, in particular the L3 part of the protein, may be critical also to transcriptional-independent apoptosis [70]. Of particular note is the finding that Chk2 may regulate transcriptional-independent p53-mediated apoptosis in response to DNA-damage created through ionizing irradiation [71]. Interestingly, Krajewski et al [72] reported low expression of Bax assessed by immunostaining to be associated with a low response to chemotherapy in metastatic breast cancer. Although no conclusion should be drawn at this stage, together these findings are consistent with the challenging hypothesis that transcription-independent activation of Bax following Chk2-phosphorylation may represent a key pathway in p53 dependent cell death in breast cancer in vivo.
###end p 102
###begin p 103
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Palmero1">[73]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Sekaric1">[74]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Khan1">[75]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Christophorou2">[76]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Efeyan2">[77]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bates1">[28]</xref>
###xml 234 239 <span type="species:ncbi:9606">human</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
p14 acts by releasing p53 from MDM2 binding, and has been related to oncogene-induced p53 activation [73]. Recently, p14 was shown to affect p53 by additional mechanisms, including acetylations [74], response to ionizing radiation in human fibroblasts [75], and tumor-suppression following ionizing radiation in mice [76], [77]. These findings further links the retinoblastoma and p53 pathways [28]. As such, we believe the negative finding with respect to its role in chemoresistance adds important information.
###end p 103
###begin p 104
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-KandiolerEckersberger1">[15]</xref>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 180 184 180 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Bertheau1">[16]</xref>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
Contrasting earlier findings by us and others [15], a recent study revealed TP53 mutations to be associated with increased likelihood of having a complete response to chemotherapy [16]. These results may not necessarily be at conflict. In the latter study, patients received treatment with a "dose-dense" chemotherapy regimen; if confirmed, the combined data may outline a therapeutic indication for aggressive dose-dense therapy based on tumor TP53/CHEK2 status.
###end p 104
###begin p 105
###xml 153 156 153 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning2">[9]</xref>
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning3">[10]</xref>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 413 418 <span type="species:ncbi:9606">women</span>
So far attempts to identify single markers and, more recently, gene expression arrays predicting chemoresistance have not proved successful (see refs in [9], [10]). The findings presented here reveal for the first time defects in a functional gene cascade to be associated with drug resistance in a human cancer in vivo. Moreover, the findings are made in breast cancer, the most frequent malignant disease among women in the industrialized world, and relate to resistance to anthracyclines, the type of cytotoxic compounds most frequently employed for this malignancy.
###end p 105
###begin p 106
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 196 200 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Norberg1">[78]</xref>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 262 267 262 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 661 664 661 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003062-Lonning1">[3]</xref>
While the only study we are aware of comparing TP53 mutation status in primaries and their distant metastases suggested an increasing fraction of tumors to express mutated TP53 during progression [78], we do not know the potential contribution of either TP53 or CHEK2 mutations to drug resistance in micrometastases or in metastatic disease. Yet the finding that one of our non-functional CHEK2 mutations associated with chemoresistance (1368InsA) occurred as a somatic, not germline mutation, suggest such mutations may be selected for during tumor progression. We propose the findings presented here provide important beacons identifying a functional pathway [3] likely to be disturbed through different mechanisms in relation to therapy resistance in advanced disease.
###end p 106
###begin p 107
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHEK2</italic>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 417 424 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In conclusion, we believe our findings here that mutations in the TP53 and CHEK2 genes each may cause resistance to anthracycline therapy in primary tumors to have wide implications to future research in this area. While results from experimental systems are mandatory generating hypotheses, conflicting data from in vitro studies underlines the pivotal role of identifying defects associated with therapy resistance in vivo. Either through mutations of the genes themselves, or inactivation of this functional cascade through co-factors, we believe identification of the Chk2 - p53 axis as critical to anthracycline therapy response provides a functional clue for further investigations in this area.
###end p 107
###begin p 108
###xml 27 35 <span type="species:ncbi:9606">patients</span>
We are grateful to all the patients who participated in the study. The authors in particular recognize the significant contribution of Randi Eikeland, Clinical Cancer Research Office, Haukeland University Hospital, who was responsible for data collection and running the clinical database. We would like to thank Beryl Leirvaag and Sandra Haugen for technical assistance during the analytical procedures and Dagfinn Ekse, Hildegun Helle and Nhat Kim Duong for tissue collection and preparation.
###end p 108
###begin p 109
###xml 0 81 0 81 <title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="110">These surgeons contributed significantly by performing all the surgical biopsies:</title>
###xml 0 81 0 81 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title textid="110">These surgeons contributed significantly by performing all the surgical biopsies:</title></caption>
###xml 81 81 81 81 <col xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" span="1"/>
###xml 81 81 81 81 <col xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="center" span="1"/>
###xml 81 81 81 81 <col xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="center" span="1"/>
###xml 81 81 81 81 <colgroup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
###xml 81 81 81 81 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" colspan="3" align="left" rowspan="1"/>
###xml 81 81 81 81 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td colspan="3" align="left" rowspan="1"/></tr>
###xml 81 85 81 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Name</bold>
###xml 81 85 81 85 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1"><bold>Name</bold></td>
###xml 85 91 85 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MD/PhD</bold>
###xml 85 91 85 91 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1"><bold>MD/PhD</bold></td>
###xml 91 102 91 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Institution</bold>
###xml 91 102 91 102 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1"><bold>Institution</bold></td>
###xml 81 102 81 102 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1"><bold>Name</bold></td><td align="left" rowspan="1" colspan="1"><bold>MD/PhD</bold></td><td align="left" rowspan="1" colspan="1"><bold>Institution</bold></td></tr>
###xml 102 119 102 119 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Ellen Schlichting</td>
###xml 119 125 119 125 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD/PhD</td>
###xml 125 166 125 166 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Ullev&#229;l University Hospital, Oslo, Norway</td>
###xml 102 166 102 166 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Ellen Schlichting</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">Ullev&#229;l University Hospital, Oslo, Norway</td></tr>
###xml 166 175 166 175 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Turid Aas</td>
###xml 175 177 175 177 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD</td>
###xml 177 222 177 222 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Haukeland University Hospital, Bergen, Norway</td>
###xml 166 222 166 222 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Turid Aas</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Haukeland University Hospital, Bergen, Norway</td></tr>
###xml 222 233 222 233 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Hanne Qvist</td>
###xml 233 235 233 235 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD</td>
###xml 235 275 235 275 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Norweigian Radium Hospital, Oslo, Norway</td>
###xml 222 275 222 275 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Hanne Qvist</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Norweigian Radium Hospital, Oslo, Norway</td></tr>
###xml 275 287 275 287 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Tore Knudsen</td>
###xml 287 289 287 289 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD</td>
###xml 289 343 289 343 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">University Hospital of Northern Norway, Troms&#248;, Norway</td>
###xml 275 343 275 343 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Tore Knudsen</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">University Hospital of Northern Norway, Troms&#248;, Norway</td></tr>
###xml 343 354 343 354 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Hans Fj&#248;sne</td>
###xml 354 360 354 360 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD/PhD</td>
###xml 360 407 360 407 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">St. Olav University Hospital, Trondheim, Norway</td>
###xml 343 407 343 407 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Hans Fj&#248;sne</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">St. Olav University Hospital, Trondheim, Norway</td></tr>
###xml 407 421 407 421 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Lars Erik Krag</td>
###xml 421 423 421 423 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">MD</td>
###xml 423 471 423 471 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left" rowspan="1" colspan="1">Stavanger University Hospital, Stavanger, Norway</td>
###xml 407 471 407 471 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td align="left" rowspan="1" colspan="1">Lars Erik Krag</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Stavanger University Hospital, Stavanger, Norway</td></tr>
###xml 81 471 81 471 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><tr><td colspan="3" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Name</bold></td><td align="left" rowspan="1" colspan="1"><bold>MD/PhD</bold></td><td align="left" rowspan="1" colspan="1"><bold>Institution</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ellen Schlichting</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">Ullev&#229;l University Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Turid Aas</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Haukeland University Hospital, Bergen, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanne Qvist</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Norweigian Radium Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Tore Knudsen</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">University Hospital of Northern Norway, Troms&#248;, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hans Fj&#248;sne</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">St. Olav University Hospital, Trondheim, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Lars Erik Krag</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Stavanger University Hospital, Stavanger, Norway</td></tr></tbody>
###xml 81 471 81 471 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td colspan="3" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Name</bold></td><td align="left" rowspan="1" colspan="1"><bold>MD/PhD</bold></td><td align="left" rowspan="1" colspan="1"><bold>Institution</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ellen Schlichting</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">Ullev&#229;l University Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Turid Aas</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Haukeland University Hospital, Bergen, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanne Qvist</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Norweigian Radium Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Tore Knudsen</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">University Hospital of Northern Norway, Troms&#248;, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hans Fj&#248;sne</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">St. Olav University Hospital, Trondheim, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Lars Erik Krag</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Stavanger University Hospital, Stavanger, Norway</td></tr></tbody></table>
###xml 0 471 0 471 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="N0x1cc2570N0x20e85a0" position="float"><caption><title textid="110">These surgeons contributed significantly by performing all the surgical biopsies:</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><tbody><tr><td colspan="3" align="left" rowspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Name</bold></td><td align="left" rowspan="1" colspan="1"><bold>MD/PhD</bold></td><td align="left" rowspan="1" colspan="1"><bold>Institution</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Ellen Schlichting</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">Ullev&#229;l University Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Turid Aas</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Haukeland University Hospital, Bergen, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanne Qvist</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Norweigian Radium Hospital, Oslo, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Tore Knudsen</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">University Hospital of Northern Norway, Troms&#248;, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Hans Fj&#248;sne</td><td align="left" rowspan="1" colspan="1">MD/PhD</td><td align="left" rowspan="1" colspan="1">St. Olav University Hospital, Trondheim, Norway</td></tr><tr><td align="left" rowspan="1" colspan="1">Lars Erik Krag</td><td align="left" rowspan="1" colspan="1">MD</td><td align="left" rowspan="1" colspan="1">Stavanger University Hospital, Stavanger, Norway</td></tr></tbody></table></table-wrap>
These surgeons contributed significantly by performing all the surgical biopsies:NameMD/PhDInstitutionEllen SchlichtingMD/PhDUlleval University Hospital, Oslo, NorwayTurid AasMDHaukeland University Hospital, Bergen, NorwayHanne QvistMDNorweigian Radium Hospital, Oslo, NorwayTore KnudsenMDUniversity Hospital of Northern Norway, Tromso, NorwayHans FjosneMD/PhDSt. Olav University Hospital, Trondheim, NorwayLars Erik KragMDStavanger University Hospital, Stavanger, Norway
###end p 109
###begin title 110
These surgeons contributed significantly by performing all the surgical biopsies:
###end title 110
###begin title 111
References
###end title 111
###begin article-title 112
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
###end article-title 112
###begin article-title 113
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
###end article-title 113
###begin article-title 114
Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.
###end article-title 114
###begin article-title 115
###xml 120 128 <span type="species:ncbi:9606">patients</span>
retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
###end article-title 115
###begin article-title 116
Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
###end article-title 116
###begin article-title 117
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
###end article-title 117
###begin article-title 118
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
###end article-title 118
###begin article-title 119
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
###end article-title 119
###begin article-title 120
Breast cancer prognostication and prediction in the postgenomic era.
###end article-title 120
###begin article-title 121
Genomics in breast cancer-therapeutic implications.
###end article-title 121
###begin article-title 122
Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM.
###end article-title 122
###begin article-title 123
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
###end article-title 123
###begin article-title 124
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
###end article-title 124
###begin article-title 125
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
###end article-title 125
###begin article-title 126
###xml 106 114 <span type="species:ncbi:9606">patients</span>
TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
###end article-title 126
###begin article-title 127
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
###end article-title 127
###begin article-title 128
Regulation of the p53 transcriptional activity.
###end article-title 128
###begin article-title 129
Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks.
###end article-title 129
###begin article-title 130
###xml 52 57 <span type="species:ncbi:9606">human</span>
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.
###end article-title 130
###begin article-title 131
DNA damage-induced activation of p53 by the checkpoint kinase Chk2.
###end article-title 131
###begin article-title 132
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner.
###end article-title 132
###begin article-title 133
###xml 62 72 <span type="species:ncbi:7227">Drosophila</span>
Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila.
###end article-title 133
###begin article-title 134
###xml 63 68 <span type="species:ncbi:9606">human</span>
The Chk2 tumor suppressor is not required for p53 responses in human cancer cells.
###end article-title 134
###begin article-title 135
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
###end article-title 135
###begin article-title 136
Increased risk of breast cancer associated with CHEK2*1100delC.
###end article-title 136
###begin article-title 137
Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
###end article-title 137
###begin article-title 138
The INK4A/ARF locus and its two gene products.
###end article-title 138
###begin article-title 139
p14ARF links the tumour suppressors RB and p53.
###end article-title 139
###begin article-title 140
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
###end article-title 140
###begin article-title 141
Tumour biology: Policing of oncogene activity by p53.
###end article-title 141
###begin article-title 142
The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
###end article-title 142
###begin article-title 143
Assessment of response to therapy in advanced breast cancer.
###end article-title 143
###begin article-title 144
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
###end article-title 144
###begin article-title 145
Study of suboptimum treatment response: lessons from breast cancer.
###end article-title 145
###begin article-title 146
###xml 92 97 <span type="species:ncbi:9606">human</span>
Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene.
###end article-title 146
###begin article-title 147
###xml 43 48 <span type="species:ncbi:9606">human</span>
Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism.
###end article-title 147
###begin article-title 148
Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA.
###end article-title 148
###begin article-title 149
Primer of Biostatistics McGraw Hill.
###end article-title 149
###begin article-title 150
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains.
###end article-title 150
###begin article-title 151
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
###end article-title 151
###begin article-title 152
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.
###end article-title 152
###begin article-title 153
###xml 90 95 <span type="species:ncbi:9606">human</span>
IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer.
###end article-title 153
###begin article-title 154
Analysis of CHK2 in vulval neoplasia.
###end article-title 154
###begin article-title 155
Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.
###end article-title 155
###begin article-title 156
Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway.
###end article-title 156
###begin article-title 157
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.
###end article-title 157
###begin article-title 158
Characterization of tumor-associated Chk2 mutations.
###end article-title 158
###begin article-title 159
Germline TP53 mutations and Li-Fraumeni syndrome.
###end article-title 159
###begin article-title 160
Chemotherapy response and resistance.
###end article-title 160
###begin article-title 161
Live or let die: The cell's response to p53.
###end article-title 161
###begin article-title 162
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
###end article-title 162
###begin article-title 163
ATM and ATR: networking cellular responses to DNA damage.
###end article-title 163
###begin article-title 164
Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues.
###end article-title 164
###begin article-title 165
CHK2 Kinase - a busy messenger.
###end article-title 165
###begin article-title 166
Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.
###end article-title 166
###begin article-title 167
p53-RI75H mutant gains new function in regulation of doxorubicin-induced apoptosis.
###end article-title 167
###begin article-title 168
Transcription-independent pro-apoptotic functions of p53.
###end article-title 168
###begin article-title 169
Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress.
###end article-title 169
###begin article-title 170
Concomitant inactivation of p53 and Chk2 in breast cancer.
###end article-title 170
###begin article-title 171
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
###end article-title 171
###begin article-title 172
Chk2 activates E2F-1 in response to DNA damage.
###end article-title 172
###begin article-title 173
###xml 80 85 <span type="species:ncbi:9606">human</span>
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
###end article-title 173
###begin article-title 174
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.
###end article-title 174
###begin article-title 175
TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains.
###end article-title 175
###begin article-title 176
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
###end article-title 176
###begin article-title 177
Is CHEK2 a cause of the Li-Fraumeni syndrome?
###end article-title 177
###begin article-title 178
###xml 72 76 <span type="species:ncbi:9696">Puma</span>
p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa.
###end article-title 178
###begin article-title 179
p53 must be competent for transcriptional regulation to suppress tumor formation.
###end article-title 179
###begin article-title 180
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis.
###end article-title 180
###begin article-title 181
p53's believe it or not: Lessons on transcription-independent death.
###end article-title 181
###begin article-title 182
Chk2 regulates transcription-independent p53-mediated apoptosis in response to DNA damage.
###end article-title 182
###begin article-title 183
###xml 135 140 <span type="species:ncbi:9606">women</span>
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
###end article-title 183
###begin article-title 184
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Activation of ARF by oncogenic stress in mouse fibroblasts is independent of E2F1 and E2F2.
###end article-title 184
###begin article-title 185
HAda3 regulates p14ARF-induced p53 acetylation and senescence.
###end article-title 185
###begin article-title 186
###xml 83 88 <span type="species:ncbi:9606">human</span>
P14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts.
###end article-title 186
###begin article-title 187
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
###end article-title 187
###begin article-title 188
Policing of oncogene activity by p53.
###end article-title 188
###begin article-title 189
Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort.
###end article-title 189
###begin p 190
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 190
###begin p 191
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the Norwegian Cancer Society, the "Rosa sloyfe" Breast Cancer Fund Raising, the Norwegian Health Region West (HelseVest) and the Innovest program of Excellence. Ranjan Chrisanthar was a recipient of a fellowship from Helse Vest. The Clinical Trial research office is financially supported by the Norwegian Cancer Society. None of the funders had any role with respect to study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 191

